According to PWC, "2023 was a reasonably strong year for the pharmaceutical and life sciences sector with both deal value and volume of M&A close to pre-pandemic levels."
Formycon and Klinge Biopharma have submitted a biologics license application for FYB203, a biosimilar for Eylea, to the FDA, according to a press release.
Coherus BioSciences (CHRS) to Acquire Exclusive U.S. Commercial Rights to FYB203 from Klinge Biopharma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
09.01.2023 - EQS-Ad-hoc: Formycon AG / Key word(s): Agreement/Alliance Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea1, in the United States . Seite 1
Formycon AG / Key word(s): Agreement/AllianceFormycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea®1, in the United States09-Jan-2023 / 13:05 CET/CESTDisclosure of an inside information acc. to Article 17.